Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977700 | 0.93 | S1PR1 (0.57) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1978063 | 0.87 | S1PR1 (0.50) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1979571 | 0.86 | S1PR5 (0.49) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1981487 | 0.85 | S1PR1 (0.50) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1978078 | 0.85 | S1PR1 (0.50) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1977951 | 0.84 | S1PR5 (0.49) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1978933 | 0.84 | S1PR5 (0.49) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1978412 | 0.84 | S1PR5 (0.49) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1977547 | 0.84 | S1PR1 (0.51) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1978561 | 0.84 | S1PR1 (0.51) | S1PR1S1PR5S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653062-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | claimed |
| EP-2504328-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-10-03 | — | — | EP | claimed |
| US-20110152241-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011066179-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-03 | — | — | WO | claimed |
| US-8653062-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2504328-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20110152241-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011066179-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152241-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 4/4885S1PR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.